Joseph Catanzaro
Stock Analyst at Mizuho Securities
(4.59)
# 923
Out of 4,504 analysts
435
Total ratings
45.7%
Success rate
12.9%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintained: Buy | $185 → $215 | $186.88 | +15.05% | 16 | Jul 6, 2026 | |
| APGE Apogee Therapeutics | Downgraded: Hold | $110 → $135 | $133.65 | +1.01% | 9 | Jun 24, 2026 | |
| TNGX Tango Therapeutics | Reiterated: Buy | $30 → $36 | $31.06 | +15.90% | 8 | Jun 8, 2026 | |
| QTTB Q32 Bio | Initiated Coverage: Buy | $14 | $11.21 | +24.89% | 1 | May 22, 2026 | |
| AVTX Avalo Therapeutics | Maintained: Buy | $39 → $45 | $19.21 | +134.25% | 3 | May 14, 2026 | |
| UPB Upstream Bio | Maintained: Buy | $51 → $50 | $7.53 | +564.01% | 2 | May 14, 2026 | |
| ERAS Erasca | Maintained: Buy | $28 → $26 | $18.53 | +40.31% | 4 | May 12, 2026 | |
| STRO Sutro Biopharma | Initiated Coverage: Buy | $50 | $29.73 | +68.18% | 1 | Apr 30, 2026 | |
| CLYM Climb Bio | Initiated Coverage: Buy | $18 | $14.00 | +28.57% | 1 | Apr 15, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $53 → $84 | $97.74 | -14.06% | 3 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 | $10.58 | +145.75% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $23.06 | +30.10% | 26 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $119.35 | - | 2 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $39.11 | +22.73% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $18 | $28.91 | -37.74% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4.5 | $0.6529 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $38 | $5.59 | n/a | 5 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3.25 | $3.76 | n/a | 15 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $53 | $76.20 | n/a | 27 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4.75 → $4.25 | $8.22 | n/a | 15 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $1.33 | n/a | 16 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.5 → $6 | $4.23 | n/a | 37 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $45 | $16.49 | n/a | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 → $38 | $56.50 | n/a | 11 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $105 → $110 | $129.83 | n/a | 20 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 → $3 | $0.7029 | n/a | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 → $15 | $11.80 | n/a | 25 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $19 | $9.68 | n/a | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $19 | $1.32 | n/a | 17 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $1.91 | n/a | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $1.90 | n/a | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 | $1.96 | n/a | 8 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $1.75 | $3.97 | n/a | 9 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $2.41 | n/a | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $10.20 | n/a | 39 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 → $26 | $31.47 | n/a | 24 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $1.75 | $1.89 | n/a | 8 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 → $1.75 | $2.51 | n/a | 4 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $39.63 | n/a | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $1.51 | n/a | 3 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $4 | $36.16 | n/a | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 → $36 | $10.04 | n/a | 4 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $17 | $1.34 | n/a | 7 | Aug 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $18 | $2.29 | n/a | 4 | Apr 7, 2020 |
Revolution Medicines
Jul 6, 2026
Maintained: Buy
Price Target: $185 → $215
Current: $186.88
Upside: +15.05%
Apogee Therapeutics
Jun 24, 2026
Downgraded: Hold
Price Target: $110 → $135
Current: $133.65
Upside: +1.01%
Tango Therapeutics
Jun 8, 2026
Reiterated: Buy
Price Target: $30 → $36
Current: $31.06
Upside: +15.90%
Q32 Bio
May 22, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $11.21
Upside: +24.89%
Avalo Therapeutics
May 14, 2026
Maintained: Buy
Price Target: $39 → $45
Current: $19.21
Upside: +134.25%
Upstream Bio
May 14, 2026
Maintained: Buy
Price Target: $51 → $50
Current: $7.53
Upside: +564.01%
Erasca
May 12, 2026
Maintained: Buy
Price Target: $28 → $26
Current: $18.53
Upside: +40.31%
Sutro Biopharma
Apr 30, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $29.73
Upside: +68.18%
Climb Bio
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $14.00
Upside: +28.57%
Spyre Therapeutics
Apr 14, 2026
Maintained: Buy
Price Target: $53 → $84
Current: $97.74
Upside: -14.06%
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $26
Current: $10.58
Upside: +145.75%
Jan 29, 2026
Maintained: Buy
Price Target: $30
Current: $23.06
Upside: +30.10%
Jan 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $119.35
Upside: -
Jan 9, 2026
Reiterated: Buy
Price Target: $48
Current: $39.11
Upside: +22.73%
Dec 18, 2025
Initiated Coverage: Hold
Price Target: $18
Current: $28.91
Upside: -37.74%
Mar 21, 2025
Maintained: Buy
Price Target: $4.5
Current: $0.6529
Upside: n/a
Mar 20, 2025
Maintained: Buy
Price Target: $36 → $38
Current: $5.59
Upside: n/a
Mar 7, 2025
Maintained: Buy
Price Target: $3.25
Current: $3.76
Upside: n/a
Mar 6, 2025
Maintained: Hold
Price Target: $53
Current: $76.20
Upside: n/a
Mar 3, 2025
Maintained: Hold
Price Target: $4.75 → $4.25
Current: $8.22
Upside: n/a
Feb 28, 2025
Maintained: Buy
Price Target: $10
Current: $1.33
Upside: n/a
Feb 28, 2025
Maintained: Hold
Price Target: $7.5 → $6
Current: $4.23
Upside: n/a
Feb 27, 2025
Maintained: Buy
Price Target: $50 → $45
Current: $16.49
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $37 → $38
Current: $56.50
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $105 → $110
Current: $129.83
Upside: n/a
Jan 29, 2025
Rated: Buy
Price Target: $15 → $3
Current: $0.7029
Upside: n/a
Jan 17, 2025
Maintained: Buy
Price Target: $40 → $15
Current: $11.80
Upside: n/a
Nov 6, 2024
Rated: Buy
Price Target: $19
Current: $9.68
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: $10 → $19
Current: $1.32
Upside: n/a
Oct 8, 2024
Rated: Buy
Price Target: $15
Current: $1.91
Upside: n/a
Sep 16, 2024
Reiterated: Buy
Price Target: $10 → $8
Current: $1.90
Upside: n/a
Sep 16, 2024
Rated: Buy
Price Target: $30
Current: $1.96
Upside: n/a
Aug 27, 2024
Downgraded: Hold
Price Target: $5 → $1.75
Current: $3.97
Upside: n/a
Apr 22, 2024
Initiated Coverage: Buy
Price Target: $20
Current: $2.41
Upside: n/a
Apr 8, 2024
Maintained: Buy
Price Target: $15
Current: $10.20
Upside: n/a
Mar 14, 2024
Rated: Buy
Price Target: $25 → $26
Current: $31.47
Upside: n/a
May 23, 2023
Downgraded: Hold
Price Target: $15 → $1.75
Current: $1.89
Upside: n/a
Sep 14, 2022
Maintained: Hold
Price Target: $1.5 → $1.75
Current: $2.51
Upside: n/a
May 31, 2022
Maintained: Buy
Price Target: $6
Current: $39.63
Upside: n/a
May 31, 2022
Maintained: Buy
Price Target: $15
Current: $1.51
Upside: n/a
May 12, 2022
Maintained: Buy
Price Target: $10 → $4
Current: $36.16
Upside: n/a
Mar 9, 2022
Maintained: Buy
Price Target: $45 → $36
Current: $10.04
Upside: n/a
Aug 21, 2020
Maintained: Buy
Price Target: $15 → $17
Current: $1.34
Upside: n/a
Apr 7, 2020
Maintained: Buy
Price Target: $28 → $18
Current: $2.29
Upside: n/a